Alan Davis
Associate Professor of Social Work & Director, Center for Psychedelic Drug Research
Data updated
Research Footprint
Alan Davis appears in 42 tracked papers (2016–2025), most studied alongside Psilocybin, 5-MeO-DMT and Ibogaine, across Depressive Disorders, Anxiety Disorders and Substance Use Disorders (SUD).
Most-cited paper: Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder (1236 citations).
Frequent co-authors: Roland Griffiths, Rafaelle Lancelotta and Nathan Sepeda.
Publication Landscape
How the 42 papers Blossom tracks for Alan Davis line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of July 2026, not a complete bibliography.
How has Alan Davis's publishing grown?
SourcedTracked papers by publication year. Click a year for the running total.
Don't read as total output: only the 42 of 42 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.
What does Alan Davis publish on?
SourcedTracked papers per topic. Orange marks the largest research focus.
Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Where does Alan Davis publish?
SourcedTracked papers per journal. Orange marks the most-used journal.
Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Background & Research
Alan K. Davis, PhD, is an Associate Professor in social work and the director of a university-based centre for psychedelic drug research and education. He has a substantive track record in both clinical and naturalistic research on classic and atypical psychedelics, combining epidemiological, mixed-method and clinical-trial approaches. Davis has collaborated with leading investigators in the field (including co-authorship on influential reviews and trial reports) and has published on topics ranging from psilocybin-assisted therapy for major depressive disorder to psychological mechanisms such as psychological flexibility and predictors of psychedelic treatment response.
His published and in-database work spans naturalistic observational studies (for example, investigations of 5-MeO-DMT use in group settings and reports of unintended improvements in depression and anxiety), mixed-method evaluations of ibogaine-assisted detoxification, research on acute and enduring effects of psychedelic use among Indigenous peoples in North America, surveys of clinician attitudes toward therapeutic psychedelic use, and analyses of changes in alcohol consumption following psychedelic experiences. Davis is known for emphasising methodological rigour in naturalistic research, pragmatic clinical outcomes, cultural and contextual factors, and safety/harm-reduction perspectives; he remains actively involved in prospective and secondary-analytic studies that aim to clarify who benefits from psychedelic interventions and why.
Key Impact
Noted for advancing epidemiological, naturalistic and mixed-method research on therapeutic and adverse outcomes of psychedelics and for translating those findings into clinical and harm-reduction contexts.
Collaboration Network
41 collaborators· click a node to visit their profile
Full network →Collaboration Network
See Alan Davis's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations Alan Davis is associated with.
Ohio State University
academicThe Ohio State University is a public land-grant research university based in Columbus, Ohio, offering undergraduate, graduate, and professional programs and conducting research across many fields. It was founded as the Ohio Agricultural and Mechanical College and serves as a major educational and economic institution in Ohio.
View stakeholder →Johns Hopkins Center for Psychedelic and Consciousness Research
The Johns Hopkins Center for Psychedelic and Consciousness Research sits within the School of Medicine in Baltimore and is one of the most established programmes of its kind. It opened in 2019 with roughly 17 million dollars in private donations, and was founded under Roland Griffiths, whose earlier psilocybin work helped revive modern clinical study of these compounds. Frederick Barrett took over as director in 2023. The centre studies how classic psychedelics such as psilocybin affect brain function, cognition and mood, and runs trials in conditions including depression, tobacco dependence and anorexia. Its scientists combine clinical trials with neuroimaging and questionnaire measures of the psychedelic experience, and much of the field's shared vocabulary traces back to work done here.
View stakeholder →